Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.
- Up to US$250 million at-the-market equity raise
- 3% sales commission to TD Cowen
- Funds targeted at DurAVR THV development
- Offering under effective SEC shelf registration
- Potential dilution and flexible issuance timing
Anteris Taps ATM Offering for DurAVR Funding
Anteris Technologies Global Corp. (ASX:AVR, NASDAQ: AVR) has quietly launched a substantial at-the-market (ATM) equity offering, authorising sales of up to US$250 million of its common stock. The move aims to bolster the company’s coffers to advance its lead product, the DurAVR® Transcatheter Heart Valve (THV) System, a cutting-edge biomimetic valve designed to treat aortic stenosis.
The offering, managed by TD Securities (USA) LLC (TD Cowen), will be conducted under an effective Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission (SEC). Anteris will pay TD Cowen a 3% commission on gross proceeds, a standard fee for this type of sales agreement. The company retains full discretion over the timing and volume of share sales, with no firm commitment to sell any specific amount.
Flexible Capital Raise Amid Clinical Progress
This ATM raise builds on Anteris’ recent capital-raising momentum, following a US$320 million raise earlier in 2026 that boosted its cash reserves to US$283 million despite a Q1 net loss of US$22.9 million. That capital injection supported the ongoing PARADIGM pivotal trial, which recently enrolled its first U.S. patients, marking a critical juncture in testing DurAVR’s safety and efficacy against established transcatheter aortic valve replacement (TAVR) devices.
DurAVR’s novel design leverages Anteris’ patented ADAPT® anti-calcification tissue technology and a single-piece biomimetic valve intended to replicate natural aortic valve function. The company is targeting a broad patient base, including younger and less-active individuals, a step beyond traditional TAVR devices designed primarily for older, high-risk patients.
The proceeds from this offering are earmarked primarily for advancing DurAVR’s development, including clinical trial progression and manufacturing scale-up, with the balance allocated to working capital and general corporate purposes. The flexible nature of the ATM allows Anteris to tap the market opportunistically, potentially smoothing funding needs as the PARADIGM trial unfolds.
Dilution Risks and Market Considerations
Investors should be mindful that the ATM structure inherently carries dilution risk. Based on the last reported Nasdaq closing price of US$9.00 per share on May 21, 2026, new investors could face immediate dilution of approximately US$4.84 per share relative to the company’s net tangible book value. The actual dilution will depend on the volume and timing of share sales, which remain at Anteris’ discretion.
Moreover, the company’s CDIs trade on the ASX under the same ticker, subject to some trading restrictions for U.S. persons that are expected to lift shortly. The dual listing enhances liquidity but also introduces complexity around cross-market trading dynamics.
Market participants will note that Anteris has agreed to file cleansing notices under Australian law to facilitate unrestricted resale of shares issued under the ATM, addressing regulatory hurdles that can otherwise hamper secondary market liquidity. However, the company retains broad discretion over the use of proceeds and timing of sales, which could impact share price volatility.
Legal and Regulatory Safeguards
Legal counsel Jones Day has provided an opinion confirming that shares issued under the sales agreement will be validly issued, fully paid, and non-assessable, subject to standard corporate approvals. The sales agreement includes customary indemnification provisions between Anteris and TD Cowen, reflecting the typical risk allocation in ATM offerings.
TD Cowen is tasked with using commercially reasonable efforts to sell shares in compliance with Nasdaq and ASX rules, but there is no guarantee of success or minimum sales volume. The company and TD Cowen each retain the right to terminate the agreement with ten days’ notice, providing flexibility to both parties amid changing market conditions.
This offering arrives as Anteris continues to ramp its pivotal PARADIGM trial, which recently benefited from U.S. Medicare reimbursement eligibility, accelerating patient enrolment and site activation. The trial’s outcome will be key to securing FDA Premarket Approval (PMA) and CE Mark clearance, critical regulatory milestones for commercialisation.
Given the company’s recent $320 million capital raise and the ongoing PARADIGM trial US enrolment, this ATM offering provides a flexible financial runway to navigate the costly clinical and regulatory pathway ahead.
Bottom Line?
Anteris’ $250 million ATM raise offers financial agility to advance DurAVR’s pivotal trial, but investors should weigh dilution risks and market timing uncertainties.
Questions in the middle?
- How will Anteris balance dilution concerns with its capital needs over the PARADIGM trial timeline?
- Could market volatility or clinical trial developments influence the pace and pricing of ATM share sales?
- What impact might this flexible equity raise have on Anteris’ negotiating power with strategic partners or acquirers?